1 hour ago
3
ARTICLE AD BOX
Kiran Mazumdar-Shaw, Biocon’s laminitis and chairperson, has identified her niece, Claire Mazumdar, arsenic the aboriginal leader.
Kiran Mazumdar-Shaw, Biocon’s laminitis and chairperson, has reportedly enactment successful spot a structured succession program for the biotechnology firm, identifying her niece, Claire Mazumdar, arsenic the aboriginal leader.Having built Biocon implicit much than 4 decades and without a nonstop heir, Mazumdar-Shaw told Fortune India successful an interrogation that she believes Claire Mazumdar is well-suited to usher the company’s adjacent phase, which is expected to beryllium shaped by advancements successful biotechnology and artificial intelligence. “I americium the sole proprietor of Biocon, and I request to marque definite that I enactment it successful bully hands,” Mazumdar-Shaw said successful the interview.
“I person seen my niece Claire arsenic my successor, due to the fact that I deliberation she has proved to maine that she tin tally a company.”
Who is Claire Mazumdar?
Claire Mazumdar, 37 years of age, presently heads Bicara Therapeutics arsenic its laminitis and CEO. The firm, which was incubated by Biocon and aboriginal listed connected NASDAQ, went nationalist successful 2024 and present has a marketplace valuation of implicit $1.6 billion. She has an world inheritance that includes degrees from Massachusetts Institute of Technology and Stanford University, on with a PhD successful crab biology, and has antecedently worked with Third Rock Ventures and Rheos Medicines.
Mazumdar-Shaw besides referred to a broader enactment web wrong the household that could lend to Biocon’s aboriginal direction, including Claire’s brother, Eric Mazumdar, a prof astatine California Institute of Technology, and her husband, Thomas Roberts, who is associated with Massachusetts General Hospital.Alongside succession planning, the institution has undertaken a broader restructuring. It has combined its generics and biologics divisions, worked connected reducing its indebtedness burden, and streamlined its wide structure.
A large absorption remains connected biosimilars, which lend astir 60% of revenue, with 12 products already commercialised and astir 20 much nether development.Leadership changes are besides successful advancement crossed radical entities. Shreehas Tambe has assumed the relation of CEO and managing manager astatine Biocon Biologics, portion Siddharth Mittal is acceptable to instrumentality complaint of Syngene International from July 1.Looking ahead, Mazumdar-Shaw indicated that Biocon’s maturation strategy volition centre connected differentiated biosimilars, the improvement of archetypal biologic therapies, and a stronger integration of artificial quality into its probe and improvement capabilities.
